AASLD 2026: MASH strategies split between GLP-1s and liver-fat siRNA
Survodutide and semaglutide analyses probe benefit beyond weight loss; Regeneron/Alnylam’s ALN-CIDEB reports large liver-fat cuts.
What moved. Chinese industry coverage of AASLD The Liver Meeting 2026 highlighted three MASH/MASLD threads from company and meeting disclosures: Boehringer’s survodutide, Novo’s semaglutide, and Regeneron/Alnylam’s siRNA ALN-CIDEB.
The numbers. In a survodutide exploratory cut, among patients with <5% weight loss, 36.8% still reached MASH resolution without fibrosis worsening. A semaglutide post hoc in BMI <27 kg/m² showed liver-marker improvement versus placebo (ALT ETR 0.61). ALN-CIDEB interim data cited ~70% mean relative liver-fat reduction by week 12 after a single dose in some cohorts, lasting to week 24.
Why it matters. The competitive map is no longer “another GLP-1 for weight.” BD and portfolio teams now have to separate metabolic agonists from liver-directed genetic knockdown—and price partnering theses accordingly.
Industry information only—not medical or investment advice.
